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ABSTRACT
Background Therapies based on targeting immune 
checkpoints have revolutionized the treatment of 
metastatic melanoma in recent years. Still, biomarkers 
predicting long- term therapy responses are lacking.
Methods A novel approach of reference- free 
deconvolution of large- scale DNA methylation data 
enabled us to develop a machine learning classifier based 
on CpG sites, specific for latent methylation components 
(LMC), that allowed for patient allocation to prognostic 
clusters. DNA methylation data were processed using 
reference- free analyses (MeDeCom) and reference- based 
computational tumor deconvolution (MethylCIBERSORT, 
LUMP).
Results We provide evidence that DNA methylation 
signatures of tumor tissue from cutaneous metastases 
are predictive for therapy response to immune checkpoint 
inhibition in patients with stage IV metastatic melanoma.
Conclusions These results demonstrate that LMC- based 
segregation of large- scale DNA methylation data is a 
promising tool for classifier development and treatment 
response estimation in cancer patients under targeted 
immunotherapy.
BACKGROUND
Malignant melanoma accounts for one of the 
most frequent cancer types and shows a rising 
incidence over the past years.1–3 Prognosis 
and treatment implications highly depend on 
the melanoma stage classified by the criteria 
of the American Joint Committee on Cancer 
(AJCC).4 5 The presence of distant metas-
tases defines stage IV and thus advanced 
melanoma4 with patients facing a consider-
ably poorer prognosis than in earlier mela-
noma stages. However, overall survival (OS) 
significantly improved due to novel therapy 
options.6 Among these, immune checkpoint 
inhibitors (ICI) modulating the anticancer 
immune response developed toward a prom-
ising treatment in tumors of various cancer 
entities.7 8 In metastatic melanoma, ICIs were 
approved as an effective therapy option. Of 
these, the combinatorial blockage of the 
immune checkpoints cytotoxic T- lymphocyte- 
associated protein 4 (ipilimumab) and 
programmed cell death protein 1 (PD-1, 
nivolumab/pembrolizumab) displayed the 
highest objective response rate in a phase III 
randomized clinical trial with 58% in the ipili-
mumab plus nivolumab arm compared with 
19% in the ipilimumab monotherapy arm.9 
Furthermore, multicenter studies have shown 
that anti- PD1- monotherapy (nivolumab, 
pembrolizumab) achieves response rates of 
up to 40% in treatment naïve patients and 
about 27%–35% in pretreated melanoma 
patients.9–12 However, treatment resistance 
to ICIs remains a relevant issue. Equally 
important, serious immune- related adverse 
events (irAE) display a major challenge, 
particularly under combinatorial therapy 
which frequently lead to discontinuation of 
ICI treatment.13 14
Unfortunately, knowledge of biomarkers 
predicting response to ICI treatment15–17 or 
the occurrence of serious irAE is still limited. 
The expression of PD-1/PD- L1 (programmed 
death- ligand 1) as predictive biomarkers for 
treatment response to ICIs remains contro-
versial15 16 and lack of PD- L1 expression in 
melanoma is not necessarily associated with 
treatment failure.18 An innovative approach 
to investigate the relation between the immu-
nological tumor microenvironment and ICI 
treatment response is the development of 
computational methods. These methods 
aim at processing and implementing large- 
scale proteomic, metabolomic, transcrip-
tomic, genetic and epigenetic data. As an 
example, the transcriptome- based algorithm 
Tumor Immune Dysfunction and Exclusion 
(TIDE) explores genes interfering with or 
promoting T- cell function.19 In this context, 
emerging genomic determinants of response 
to ICIs have been studied extensively.20 As a 
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unique feature, epigenetic signatures are subjected to 
slower and sustained transformations within the dynamic 
changes of the tumor microenvironment. Certain DNA 
methylation patterns are cell- type- specific and therefore 
deconvolution of DNA methylation data enables the anal-
ysis of cellular composition21 as well as a precise brain 
tumor classification.22 With regard to potential epigen-
etic biomarkers, a particular DNA methylation profile 
among non- small cell lung cancer tissue samples from 
patients receiving ICI treatment was associated with an 
improved outcome, whereas mere PD- L1 expression, 
levels of tumor- infiltrating lymphocytes or the mutational 
load had no prognostic effects.23 Global differential DNA 
methylation patterns between melanoma samples might 
correlate with biological behavior and immunological 
processes.24 Moreover, immune cell methylation patterns 
might serve as prognostic biomarkers in melanoma.25 
Taken together, there is still a lack of reliable biomarkers 
for the prediction of a successful therapy response after 
ICI treatment. DNA methylation profiling might be a 
robust approach for the development of prognostic or 
even predictive biomarkers in cancer, as so far, there is 
still a lack of reliable biomarkers for the prediction of a 
successful therapy response after ICI treatment.
In the current study, we investigated tumor DNA meth-
ylation patterns of two independent cohorts of melanoma 
patients using a novel computational approach of stepwise 
reference- free and reference- based tumor deconvolution 
with the aim to develop a machine learning classifier that 
allows for the prediction of a long- term therapy response 
in ICI- treated metastatic melanoma.
METHODS
Sample selection and data acquisition of the ICI melanoma 
cohort
The ICI cohort comprised cutaneous metastases of AJCC 
stage IV (eighth edition) melanoma patients treated in 
three different dermato- oncology centers (sites I–III) 
in Germany. Formalin- fixed and paraffin- embedded 
(FFPE) tissue samples (deriving from the biobank of the 
Department of Dermatology, Goethe- University, Frank-
furt am Main, Germany, from the Institute of Pathology, 
Charité—Universitätsmedizin Berlin, Berlin, Germany 
and from the Department of Dermatology, University 
Hospital Würzburg, Würzburg, Germany) treated with 
ICIs between October 2010 and December 2020 were 
included. Clinical outcome was measured as survival 
under ICI therapy (defined as the time from start of ICI 
treatment to date of decease) and OS (defined as the time 
from primary diagnosis of melanoma to date of decease). 
Additionally, radiological response to ICI treatment 
was classified by Response Evaluation Criteria in Solid 
Tumours for immune- based therapies (iRECIST: iCPD, 
confirmed progressive disease; iUPD, unconfirmed PD; 
iSD, stable disease; iPR, partial response and iCR, complete 
response). Hereby, patients with disease control (DC, 
defined as iCR, iPR or iSD in at least one ICI treatment 
approach) were discriminated from patients with progres-
sive disease (PD, defined as iUPD or iCPD). We addition-
ally included the following parameters for each patient: 
epidemiological characteristics (sex, age), BRAF and 
NRAS mutation status and brain metastases status (yes 
vs no) (detailed information on the patient cohort and 
study workflow is depicted in figure 1 and online supple-
mental table 1). Data not passing well- established quality 
controls were excluded. In case of multiple samples per 
patient at site I, we selected the representative sample per 
patient according to the minimum euclidean distance of 
its methylation profile to the median profile (figure 1). 
Finally, the ICI cohort consisted of 65 samples from 65 
patients (from sites I–III) of which 61 patients received 
complete radiological workup according to iRECIST 
(figure 1). The study protocol was endorsed by the local 
ethical committee (SNO-5-2019).
Data acquisition of the TCGA melanoma cohort
Clinical data of initially 470 patients suffering from mela-
noma were retrieved from The Cancer Genome Atlas 
(TCGA) data archive (TCGA SKCM). Clinical annota-
tions included sex, age, AJCC tumor stages and site of 
tumor resection/biopsy. As the information on exact 
AJCC tumor stages (A, B, C and D) was missing in 98 
cases, we annotated the simplified AJCC stages I–IV. 
Comprehensive data on ICI treatment or radiological 
therapy response were not eligible for this cohort. Corre-
sponding raw intensity data (IDAT) files generated by use 
of the 450 k Human Methylation Array (Illumina, San 
Diego, USA) were retrieved using the TCGA Genomic 
Data Commons tool. Data not passing well- established 
quality controls, patients with incomplete clinical annota-
tions as well as melanoma in situ patients of AJCC stage 0 
were excluded from the study resulting in 396 patients to 
set up the so- called TCGA melanoma cohort.
Human methylation EPIC array of the ICI melanoma cohort
While TCGA data were available as 450 k Human Methyla-
tion array IDATs, for the ICI cohort of stage IV melanoma 
cutaneous metastases, we used the Human Methylation 
EPIC array (Illumina, San Diego, USA) comprising over 
850 000 CpG sites by analysis of representative tissue 
punches or macrodissected 10 µm thick tumor slides from 
FFPE blocks. We followed standard protocols for tissue 
and DNA processing. Further processing of the microar-
rays and hybridization as well EPIC beadchip scanning 
were performed as indicated by the manufacturer.
DNA methylation data processing
DNA methylation data was obtained as IDAT files, which 
were used as input to the RnBeads software package. 
Quality control was performed using the built- in 
control probes on the EPIC array, and the data showed 
high overall quality. Furthermore, CpGs were filtered 
according to detection p- values, and annotated single 
nucleotide polymorphisms, sites on the sex chromosomes 
and potentially cross- reactive sites were discarded from 
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Figure 1 Consort diagram and study workflow. (A) Consort flow diagram of the retrospective study process resulting in 
the TCGA melanoma cohort (in silico data analyses) and the ICI cohort (acquisition of FFPE cutaneous metastases samples 
from melanoma stage IV patients treated with ICI at the study sites I–III). (B) Study workflow. Schematics were created using 
bioRENDER software (https://biorender.com/). FFPE, formalin- fixed and paraffin- embedded; ICI, immune checkpoint inhibitor; 
LMC, latent methylation components; TCGA, The Cancer Genome Atlas.
P
rotected by copyright.
















4 Filipski K, et al. J Immunother Cancer 2021;9:e002226. doi:10.1136/jitc-2020-002226
Open access 
the analysis.26 Methylation data were normalized using 
the “dasen” method from the wateRmelon R- package.26 
TCGA methylation data were processed analogously.
Global DNA methylation analyses
In a first approach, all eligible CpG sites passing quality 
controls in 65 tumor bulk samples were enrolled in prin-
cipal component analysis (PCA). In addition, differen-
tial methylation analysis for all eligible CpG sites using 
RnBeads was performed comparing patient groups 
with different clinical characteristics like the melanoma 
subtype, BRAF or NRAS mutation status, absence or 
presence of brain metastases or radiological DC versus 
PD according to iRECIST. Raw data IDAT files as well as 
processed data of the ICI cohort are accessible via Gene 
Expression Omnibus (https://www. ncbi. nlm. nih. gov/ 
geo/; GSE175699).
Reference-free MeDeCom analysis
DNA methylation data of the bulk tumor samples of the 
TCGA melanoma cohort and the ICI cohort were investi-
gated using the reference- free MeDeCom algorithm that 
dissects DNA methylation data into major components of 
variation, called latent methylation components (LMC).27 
DNA methylation data of melanoma patients were 
processed according to a recently published protocol.28 
The protocol selected the 5000 most variably methylated 
CpG sites across the samples as input to MeDeCom. Inves-
tigation of the cross- validation error and of the objective 
value for the parameter number of LMCs (kappa) and 
the regularization parameter (lambda) were performed, 
resulting in a set of LMCs. In order to prevent a strong 
dependence of the clustering on the LMC with the 
highest proportion across the samples, we decided to stan-
dardize the LMC proportions using z- scores. This allows 
for uncovering fine- grained changes in the LMC propor-
tions and identification of subtle differences between the 
samples. LMC proportion values were standardized by 
subtracting the respective column mean and dividing by 
the column SD. Standardization was performed for LMCs 
1–8 of all samples collectively (TCGA and ICI cohort), 
and separately in the TCGA and ICI cohort. Standardized 
LMC proportion- based clusters were further investigated 
regarding their prognostic and predictive significance. 
Hierarchical cluster analysis was performed using Ward’s 
minimum variance method.
Reference-based LUMP algorithm
To estimate the leukocyte content in the bulk tumor 
samples, the leukocyte unmethylation for purity (LUMP) 
algorithm as implemented within RnBeads was employed. 
LUMP provides leukocyte ratios from the DNA meth-
ylation data by screening for 44 CpG sites particularly 
hypomethylated in leukocytes.29 30
Reference-based MethylCIBERSORT algorithm
For a detailed deconvolution of the cellular composition 
of bulk melanoma samples, we applied the reference- 
based analysis MethylCIBERSORT. MethylCIBERSORT 
relies on DNA methylome- based reference data to infer 
distinct cellular contents (cancer cells, CD14- positive, 
CD19- positive, CD56- positive and CD8- positive cells, T 
regulatory cells, CD4- positive effector cells, eosinophils, 
fibroblasts and neutrophils). Methylation patterns of 
the sample of interest are compared with deposited cell- 
type- specific and determinating DNA methylomes.31 32 
MethylCIBERSORT analysis was carried out according 
to the respective protocols.32 Briefly, EPIC array IDAT 
sets were imported in R’s “minfi” package to perform 
quality checks, Noob normalization and acquisition of 
beta values. Using the “MethylCIBERSORT” R package, 
a mixture file was built whose matrix consisted of beta 
values for comparison to a reference matrix (provided 
by TRF). This reference file contained signature meth-
ylation beta values of well- characterized cell types. After 
generating the mixture file, mixture and reference files 
were uploaded onto the CIBERSORT portal and decon-
voluted (provided by the Alizadeh Lab, Stanford Univer-
sity, USA, developed by Newman et al31).
Patient classifier
A patient classifier based on the 5000 most variable meth-
ylated CpGs selected for MeDeCom tumor deconvolution 
was developed for patient allocation to predictive LMC 
proportion- based clusters. Based on these CpG sites, 
we employed logistic regression using Lasso regulariza-
tion (glmnet R- package)33 to predict whether a tumor 
sample would belong to the beneficial LMC proportion- 
based cluster or to the less beneficial cluster. Finally, this 
shrinkage led to 20 predictive CpGs. We employed nested 
10- fold cross- validation to estimate model performance 
and the hyperparameter lambda simultaneously.
Statistics
All statistical analyses were conducted using either JMP16 
(SAS, Cary, USA) or R (R Core Team, 2019). The non- 
parametric Wilcoxon’s test was applied for comparisons 
of data distributions between two groups. Kaplan- Meier 
survival curves were compared by log- rank and Wilcox-
on’s test. Likelihood ratios and risk ratios were computed 
in univariate proportional hazard models. Hierarchical 
clustering was performed by use of the Ward’s minimum 
variance method.
RESULTS
Workflow and cohort statistics
To identify prognostic DNA methylation signatures in 
melanoma patients, we first performed global approaches 
for dimensional reduction of large- scale DNA methylome 
data. As a next step, we used reference- free and reference- 
based tumor deconvolution analyses, which allowed for 
development of a patient classifier and a biological inter-
pretation of results (figure 1). The TCGA melanoma 
cohort comprised 396 tumor samples located in skin, soft 
tissue, central nervous system, peripheral, non- central 
nervous system organs and lymph nodes, respectively. 
P
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Tumors from all AJCC tumor stages I–IV were included 
(figure 1). For validation of the TCGA cohort statis-
tics, we performed Kaplan- Meier survival analysis which 
revealed that the applied simplified AJCC stages I–IV 
were prognostic (figure 2A). The ICI cohort included 
tissue from cutaneous metastases of 65 patients with AJCC 
stage IV melanoma treated with ICI therapy exclusively. 
Regarding the mutational status, 45.3% of the primary 
tumors showed a BRAF mutation, while 25.6% were NRAS 
mutant. Brain metastases were observed in 40% of all 
patients (online supplemental table 1). We assessed OS, 
survival under ICI treatment as well as the radiological 
disease response assigning patients to either DC or PD. 
The Kaplan- Meier analysis of the survival under ICI 
therapy stresses a benefit in patients responding to ICI 
therapy according to the iRECIST criteria, thus proving 
cohort stringency (figure 2A).
Global DNA methylation analysis does not decipher distinct 
signatures for melanoma subgroups
In a first approach, we assessed global DNA methylation 
patterns including all eligible CpG sites that might differ 
between subgroups of the well- characterized cohort of 
stage IV melanoma patients treated with ICI. Using PCA 
Figure 2 MeDeCom reference- free DNA methylome- based tumor deconvolution and standardized clustering of the total study 
population. (A) Kaplan- Meier survival curves indicating patient outcome characteristics of the different cohorts of the study: 
TCGA cohort (396 stages I–IV melanoma patients), total cohort (TCGA cohort plus ICI cohort including 65 patients with stage 
IV melanoma under ICI treatment (highlighted as orange dots)) and the ICI cohort discriminated by patients with progressive 
disease (PD) and disease control (DC) under ICI therapy, defined according to the neuroradiological iRECIST criteria. Survival 
times (weeks) were compared by log- rank and Wilcoxon test (p- values depicted). (B) By use of the reference- free tumor 
deconvolution algorithm MeDeCom, eight LMCs were identified in the total patient cohort (TCGA+ICI cohort). Heatmap showing 
the standardized proportions of the LMCs in all patient samples of the total cohort (rows, n=461, cohort and melanoma stage 
depicted). Number of patients in parentheses. ICI, immune checkpoint inhibitor; LMC, latent methylation components; TCGA, 
The Cancer Genome Atlas.
P
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neither BRAF/NRAS mutational status, brain metastases 
status, nor radiological response status showed a clear 
association to the principal components (online supple-
mental figure 1A). Accordingly, differential methylation 
analysis did not reveal major differentially methylated 
CpGs (online supplemental figure 1B). This emphasizes 
that there is no global DNA methylation state associ-
ated with any of the available clinicopathological sample 
annotations.
Reference-free MeDeCom analysis of the total study 
population and reference-based deconvolution algorithms of 
TCGA DNA methylation data
Since the initial global DNA methylation analyses (PCA 
and differential methylation) of the stage IV melanoma 
cohort did not reveal an association with ICI therapy, we 
aimed for a more refined yet profound and reference- free 
algorithm to assess potential prognostic and predictive 
methylation signatures. Therefore, we first applied the 
MeDeCom algorithm to the bulk tumor DNA methyla-
tion data of the combined TCGA and ICI cohort (param-
eter selection is depicted in online supplemental figures 
2). Overall, the cross- validation error pointed to selecting 
eight components (parameter k) and the regularization 
parameter λ as 0.001. The proportions of the eight LMCs 
(LMC1-8) across the samples are visualized in figure 2B. 
Hierarchical cluster analysis of LMC proportion Z- scores 
of the entire cohort (TCGA+ICI) did not reveal clear clus-
tering according to the cohort (TCGA vs ICI) and clusters 
did not show a clear association with AJCC tumor stages 
(figure 2B). In a next step, we analyzed the prognostic 
impact of LMC proportion- based clustering on OS of the 
TCGA cohort. Cluster analysis revealed two main clusters 
(1 vs 2, figure 3A). Although, patients of cluster 1 showed 
a trend toward a better OS in the total TCGA cohort as 
well as in AJCC stages II and IV, log- rank and Wilcoxon’s 
test did not indicate statistical significance (figure 3B). 
MeDeCom is a reference- free deconvolution algorithm 
of DNA methylation data, which generates LMCs and 
their proportions and follows dominant cell types. As we 
were interested in distinct cellular composition of LMC 
proportion- based clusters and as MeDeCom does not 
compare data to cell- type specific reference methylation 
profiles, we further investigated LMC proportion- based 
clusters 1 and 2 using the reference- based algorithms 
LUMP and MethylCIBERSORT.
Interestingly, the cancer cell fraction was significantly 
lower in the rather beneficial cluster 1, whereas immune 
and stromal cells were strongly increased in cluster 1 
(figure 3D and online supplemental figure 3A,B). Taking 
a closer look at immune cell subtypes, especially CD8- 
positive T cells, B- cells, NK cells but also myeloid CD14- 
positive cells were enriched in cluster 1. On the contrary, 
CD4- positive T cells were significantly reduced in cluster 
1. In summary, this indicates that LMC proportion- based 
clusters might be of prognostic relevance in certain 
subgroups of melanomas in a heterogenous melanoma 
cohort. However, a precise interpretation of LMCs with 
regard to immune biological processes remains elusive.
Reference-free MeDeCom analysis of DNA methylation data 
exhibits predictive clusters in immune checkpoint inhibitor 
treated metastatic melanoma
In search of predictive signatures of large- scale DNA meth-
ylation data, we further investigated cutaneous metastases 
of stage IV melanoma patients receiving immune check-
point inhibition in three dermato- oncology centers in 
Germany. Based on our initial MeDeCom analysis which 
decomposes DNA methylation data of the total cohort into 
eight LMCs, we performed LMC proportion- based unsu-
pervised hierarchical cluster analysis in the ICI cohort 
only (figure 4A). Hierarchical cluster analysis depicted 
two major clusters with an enrichment of patients with 
DC in cluster 2 (figure 4A,B). In line with this, survival 
calculated from the initiation of ICI treatment was signifi-
cantly longer in cluster 2 patients (figure 4C) and cluster 
2 was predictive for survival from initiation of ICI treat-
ment in univariate analysis (figure 4D). The median 
duration of ICI treatment as an indirect marker for DC 
and treatment tolerability accounted for 183 days in the 
beneficial cluster 2 as compared with 90 days in cluster 1 
(Wilcoxon’s non- parametric test p=0.03).
Additional MethylCIBERSORT facilitated a micro-
environmental analysis of the tumor samples allocating 
to the predictive LMC- based clusters in the ICI cohort. 
While the cancer cell fraction, as well as most immune 
cell subsets did not show significant differences between 
the beneficial cluster 2 and cluster 1, only regulatory T 
cells (Tregs), CD56- positive (NK) cells and fibroblasts 
were depleted in cluster 2 (figure 4E and online supple-
mental figure 3). Timing of biopsy (before vs under 
ongoing ICI treatment) did not have a substantial impact 
on the cellular composition of tumor bulks with solely the 
fraction of CD56- positive NK cells being enriched after 
initiation of ICI treatment (online supplemental figure 
4). In summary, MeDeCom analysis unraveled predictive 
signatures for DC in metastatic melanoma being treated 
with ICI.
LMC-based classifier allows for patient stratification into 
predictive clusters
Finally, the findings of reference- free methylome analyses 
in the ICI cohort were integrated to develop a patient 
classifier with the aim to allocate patients to the predic-
tive LMC proportion- based cluster. Therefore, we used 
the 5000 CpGs computed by MeDeCom as an input for a 
logistic regression analysis. Lasso regularization revealed 
20 of these 5000 CpG sites to predict sample allocation to 
the less favorable cluster 1 or the favorable cluster 2 of the 
ICI cohort (figure 4F). By means of this classifier model, 
we achieved a cross- validated accuracy of 89.5% as well as 
an area under the curve of the receiver operating charac-
teristic curve of 0.9664 in our cohort of melanoma stage 
IV patients under ICI treatment (figure 4G).
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DISCUSSION
Malignant melanoma ranges among the top cancer 
diseases and its incidence is rising gradually.1–3 Immuno-
modulatory treatment approaches aiming to reinvigorate 
an exhausted lymphocytic immune response against 
tumor cells mainly by targeting immune checkpoints led 
to a substantial prognostic improvement in advanced 
melanoma.34 35 Due to a limited response to ICI therapy 
Figure 3 MeDeCom reference- free DNA methylome- based tumor deconvolution and standardized LMC- based clustering of 
the TCGA melanoma cohort. (A) Heatmap of the patient samples of the TCGA cohort (rows, n=396, melanoma stage depicted) 
showing the proportions of the eight LMCs that were previously identified by MeDeCom analysis of the total patient cohort 
(TCGA+ICI cohort) and then standardized in the TCGA cohort before clustering. Hierarchical clustering of standardized LMC 
values revealed two distinct clusters (1=blue, 2=black). (B) Kaplan- Meier survival curves regarding patient allocation to LMC- 
based cluster 1 vs 2 in the total TCGA cohort including all stages and in stages I–IV, respectively. Overall survival (weeks) was 
compared by log- rank and Wilcoxon test (p- values depicted). (C) Forest plot of TCGA cohort univariate proportional hazard 
analyses for the variables age at diagnosis, sex, melanoma stage and the LMC- based cluster 1 vs 2. (D) Tumor deconvolution 
of the TCGA melanoma cohort was performed by the reference- based MethylCIBERSORT algorithm. The proportions of the 
respective cell fractions in melanoma samples of patients belonging to LMC- based cluster 1 (blue) were compared with patients 
belonging to LMC- based cluster 2 (black) by non- parametric Wilcoxon’s test (significant p- values depicted). Number of patients 
in parentheses. ICI, immune checkpoint inhibitor; LMC, latent methylation components; TCGA, The Cancer Genome Atlas.
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along with potentially severe irAEs, the identification of 
predictive biomarkers to improve patient selection for 
ICI treatment is crucial. Some microenvironmental and 
genomic predictors for ICI treatment response were iden-
tified over the past few years.20 These predictors include 
the expression of tumor antigens and neoantigens, the 
mutational burden, alterations in antigen presentation, 
DNA mismatch- repair and Interferon-γ signaling, among 
others.20 Still, harmonization of applied assays, such as 
PD- L1 testing is pending.36 Predictive biomarkers cannot 
Figure 4 MeDeCom reference- free DNA methylome- based tumor deconvolution and standardized LMC- based clustering 
of stage IV melanoma patients under ICI therapy reveals predictive signatures. (A) Heatmap of the patient samples of the ICI 
cohort (rows, n=65, ICI response defined by iRECIST depicted) showing the proportions of the eight LMCs that were previously 
identified by MeDeCom analysis of the total patient cohort (TCGA+ICI cohort) and then standardized in the ICI cohort before 
clustering. Hierarchical clustering of standardized LMC values revealed two distinct clusters (1=black, 2=green). (B) Proportion 
of patients with progressive disease (PD, purple) and disease control (DC, green) defined by iRECIST in cluster 1 and cluster 
2, respectively. Patients lost to iRECIST follow- up (n=4, NA=not available) were not included into further outcome analyses. (C) 
Kaplan- Meier survival curves separating patients allocated to LMC- based cluster 1 vs 2 of the ICI cohort. Survival from the start 
of ICI therapy (weeks) was compared by log- rank and Wilcoxon test (p- values depicted). (D) Forest plot of ICI cohort univariate 
proportional hazard analyses for the variables age at diagnosis, sex, BRAF and NRAS mutation status, brain metastasis status 
and the LMC- based cluster 1 vs 2 (significant p- values depicted). (E) Tumor deconvolution of the ICI cohort was performed by 
the reference- based MethylCIBERSORT algorithm. The proportions of the respective cell fractions in melanoma samples of 
patients belonging to the favorable LMC- based cluster 2 (green) were compared with patients belonging to LMC- based cluster 
1 (black) by non- parametric Wilcoxon’s test (significant p- values depicted). (F) Classifier development with (G) receiver operating 
characteristic curve of the prediction model. Number of patients in parentheses. AUC, area under the curve; ICI, immune 
checkpoint inhibitor; LMC, latent methylation components; TCGA, The Cancer Genome Atlas.
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be reduced to single parts of the dynamic immune 
cascade and require the invention of more precise tools 
that are readily applicable in clinical routine. In this 
context, the analysis of epigenomic signatures especially 
DNA methylation- based approaches appear to be a prom-
ising candidate.24 25
In the present study, we introduced a novel approach 
for the analysis of DNA methylation data from melanoma 
bulk samples by refining (i) global, (ii) reference- free 
and (iii) reference- based algorithms. This strategy turned 
out as a valid tool to decipher prognostic methylation 
signatures in melanoma patients and ultimately allowed 
the development of a classifier for ICI response in stage 
IV melanoma patients.
Global analyses of DNA methylation data failed to 
discriminate reliable prognostic or predictive signatures. 
This argued for a refinement of computational algo-
rithms. By use of the reference- free tumor deconvolution 
algorithm MeDeCom,27 we were able to avoid the limita-
tions imposed through a reference data set24 and gained 
a comprehensive view on the epigenetic tumor profiles. 
This approach is in contrast with previous studies that 
are mostly limited to reference- based tumor deconvolu-
tion algorithms which narrow down the amount of data 
entering the computation of prognostic methylation signa-
tures.25 Based on clustering of LMC- proportion Z- scores, 
MeDeCom revealed signatures in stages I–IV melanoma 
patients of the TCGA cohort which were characterized by 
a distinct cellular composition but only showed a trend 
toward a prognostic relevance. The microenvironmental 
compositions of the samples were investigated by LUMP 
and MethylCIBERSORT representing reference- based 
deconvolution algorithms.21 32 Chakravarthy et al were 
among the first to deconvolute tumors by means of DNA 
methylomes.32 Estimation of tumor purity and cellular 
microenvironmental composition allowed for allocation 
to immune hot and cold tumors.32 The association of the 
LMC- based clusters of the TCGA cohort with a partic-
ular microenvironmental composition might be relevant 
in earlier stage melanoma patients. However, the inter-
pretation of outcome parameters in the TCGA cohort 
is limited due to the sampling heterogeneity including 
tissue from different organs, patients in different clinical 
stages (with only few stage IV patients) and only limited 
clinical annotations. Therefore, this aspect should be 
investigated in larger data sets of clinically harmonized 
melanoma cohorts. To investigate the predictive value 
of methylation signatures, we compiled a comparatively 
large cohort of stage IV melanoma patients that received 
ICI treatment. We were able to identify a predictive 
value of LMC proportion- based clusters correlating with 
survival under ICI treatment.
To understand potential biological mechanisms 
behind the predictive LMC proportion- based clusters, 
we amended reference- based deconvolution of the DNA 
methylation data.
In the ICI cohort, we did not find a distinct cell signa-
ture which was associated with the prognostic clusters 
and long- term DC. Recent studies reported the pres-
ence of B cells and so- called tertiary lymphoid structures 
to be associated with improved survival and a response 
to ICI therapy in melanoma.37 38 In contrast, Mitra et al 
investigated DNA methylation clusters based on median 
methylation values of selected immune cell- specific genes 
in melanoma patients but failed bringing forth an ICI 
response prediction signature.25
The superior goal of a successful anticancer therapy 
is a long- term clinical benefit. Immunotherapy can lead 
to remarkable responses which can be objectified by 
imaging techniques. Unfortunately, even after showing 
an initial clinical or radiological response (assessed e.g. by 
the iRECIST), a considerable number of patients develop 
disease progression. Interestingly, our data show that LMC 
proportion- based clustering in ICI- treated melanoma can 
predict a durable long- term effect on ICI therapy reflected 
by a prolongation of survival after ICI treatment was initi-
ated. Therefore, we aimed at integrating the findings to 
develop a pilot patient classifier that allowed to allocate 
melanoma patients under ICI treatment to the predictive 
LMC proportion- based clusters. This is a first step toward 
the development of a tool readily applicable in a clinical 
setup. At this early stage, it should be noted that our clas-
sifier has to be considered as a pilot tool established in a 
small patient cohort that yet has to be validated in larger, 
prospective settings to control for both clinical and radio-
logical response parameters.
Taken together, our data demonstrate the benefit of 
reference- free deconvolution of DNA methylation data 
for cancer stratification. The obtained prognostic LMC 
proportion- based clusters have a very good predictive 
value for ICI treatment response in metastatic melanoma. 
The combined deconvolution approaches of bulk tumor 
DNA methylation data show a new way to develop a clas-
sifier to predict response to ICI treatment in melanoma. 
Further studies will be needed to validate this in larger 
cohorts of cancer patients treated with immunotherapy.
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ICI response (DC disease control, 
PD progressive disease, UNK 
unknown) 
FFM_1 female 61 0 NA 0 pre-ICI  IV 498 DC 
FFM_2 female 75 0 0 0 pre-ICI  IV 334 PD 
FFM_3 female 76 0 0 0 pre-ICI  IV 35 PD 
FFM_4 male 79 0 1 0 post-ICI IV 624 DC 
FFM_5 female 74 0 1 1 pre-ICI  IV 770 PD 
FFM_6 female 83 0 0 0 post-ICI IV 1154 PD 
FFM_7 male 52 1 NA 1 post-ICI IV 110 DC 
FFM_8 female 73 1 0 0 pre-ICI  IV 105 DC 
FFM_9 male 70 0 1 1 pre-ICI  IV 510 PD 
FFM_10 male 72 0 1 0 pre-ICI  IV 210 DC 
FFM_11 male 86 1 0 1 pre-ICI  IV 168 DC 
FFM_12 male 54 0 0 0 pre-ICI  IV 167 DC 
FFM_13 female 48 1 0 0 pre-ICI  IV 0 PD 
FFM_14 female 44 1 0 1 post-ICI IV 51 PD 
FFM_15 female 72 0 0 0 pre-ICI  IV 126 PD 
FFM_16 male 53 0 1 1 pre-ICI  IV 64 PD 
FFM_17 male 76 1 0 0 pre-ICI  IV 926 DC 
FFM_18 male 40 1 0 1 pre-ICI  IV 141 PD 
FFM_19 female 73 1 0 0 pre-ICI  IV 672 DC 
FFM_20 male 66 0 0 1 pre-ICI  IV 1057 DC 
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FFM_21 male 79 0 0 0 pre-ICI  IV 568 PD 
FFM_22 male 53 1 NA 1 pre-ICI  IV 49 PD 
FFM_23 male 61 0 1 1 pre-ICI  IV 1029 DC 
FFM_24 male 43 0 1 1 post-ICI IV 907 DC 
FFM_25 male 89 1 0 0 pre-ICI  IV 293 PD 
FFM_26 male 69 1 0 0 pre-ICI  IV 63 DC 
FFM_27 male 46 1 NA 0 pre-ICI  IV 870 DC 
FFM_28 female 41 0 NA 1 pre-ICI  IV 63 PD 
FFM_29 male 52 1 NA 1 post-ICI IV 63 PD 
FFM_30 female 43 1 0 1 post-ICI IV 142 PD 
FFM_31 female 68 0 NA 0 post-ICI IV 64 PD 
FFM_32 male 72 0 1 1 pre-ICI  IV 301 PD 
FFM_33 female 75 0 NA 1 post-ICI IV 43 DC 
FFM_34 female 85 0 NA 1 pre-ICI  IV 64 PD 
FFM_35 male 65 0 NA 1 pre-ICI  IV 69 PD 
FFM_36 male 43 1 0 1 pre-ICI  IV 115 PD 
FFM_37 female 46 0 NA 1 post-ICI IV 61 PD 
FFM_38 female 68 0 0 1 post-ICI IV 1529 PD 
FFM_39 male 56 1 NA 0 post-ICI IV 1793 DC 
B_1 male 71 1 0 0 pre-ICI  IV 334 PD 
B_2 female 46 0 NA 0 pre-ICI  IV 305 DC 
B_3 male 37 0 1 0 post-ICI IV 238 PD 
B_4 male 73 0 1 0 pre-ICI  IV 1257 DC 
B_5 female 61 1 0 1 pre-ICI  IV 179 PD 
B_6 female 73 1 0 0 pre-ICI  IV 181 PD 
B_7 male 59 1 0 1 pre-ICI  IV 153 PD 
B_8 male 82 1 0 0 post-ICI IV 171 PD 
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B_9 female 56 1 0 0 pre-ICI  IV 155 PD 
B_10 male 71 NA NA 0 pre-ICI  IV 100 UNK 
B_11 female 53 1 0 1 pre-ICI  IV 151 PD 
B_12 male 82 1 0 0 post-ICI IV 700 PD 
B_13 female 83 0 0 0 post-ICI IV 1339 DC 
B_14 male 63 0 0 0 post-ICI IV 183 PD 
WUE_1 male 80 1 NA 0 pre-ICI  IV 736 DC 
WUE_2 male 62 1 NA 0 pre-ICI  IV 68 PD 
WUE_3 male 66 0 NA 1 pre-ICI  IV 58 PD 
WUE_4 male 60 1 NA 1 pre-ICI  IV 0 UNK 
WUE_5 male 75 0 NA 0 pre-ICI  IV 0 UNK 
WUE_6 female 67 0 NA 0 pre-ICI  IV 46 DC 
WUE_7 male 75 1 NA 0 pre-ICI  IV 505 DC 
WUE_8 female 63 0 NA 0 pre-ICI  IV 63 PD 
WUE_9 male 63 0 NA 0 pre-ICI  IV 63 UNK 
WUE_10 female 54 1 NA 0 pre-ICI  IV 105 PD 
WUE_11 female 71 0 NA 0 pre-ICI  IV 70 PD 
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Supplementary data 
 
Supplementary Figure 1: Neither genetic melanoma subtype, brain metastasis status nor 
response to ICI therapy translate into global DNA methylation patterns in ICI treated stage 
IV melanoma patients. 
(A) Principal component analyses and (B) plotting of group-wise average DNA methylation 
values for CpG sites of 65 melanoma patients based on BRAF mutation status, NRAS 
mutation status, presence or absence of brain metastases and the response status to ICI 
therapy defined as progressive disease (PD) or disease control (DC). (B) Differentially 
methylated regions according to a p-value below 1x10-5 are marked in red. 
Supplementary Figure 2: Parameter selection for MeDeCom analysis in the total cohort 
(TCGA + ICI cohort).  
(A) Cross validation error plotted against the number of LMCs k. Cross validation error 
tends to decrease with more components being included and we selected k=8 as the value 
where the error starts to level out. (B) Selection of the regularization parameter λ for k=8. 
We selected λ=0.001 as the point where the cross-validation error is still low, while the 
objective function tends to increase. 
Supplementary Figure 3: Reference-based tumor deconvolution of the DNA methylome 
by LUMP and MethylCIBERSORT indicates a microenvironmental signature of a particular 
LMC-based cluster of the TCGA cohort and no major differences in the LMC-based 
clusters of the ICI cohort.  
Tumor deconvolution of the TCGA melanoma cohort (A, B) and the ICI cohort (C, D), 
respectively, was performed by the reference-based (A, C) LUMP and (B, D) 
MethylCIBERSORT algorithm. The LUMP estimate ratio and proportions (in percent) of the 
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respective cell type were compared between patients belonging to the distinct LMC-based 
clusters 1 and 2 using the non-parametric Wilcoxon’s test (significant p-values in bold 
italics, number of patients in parentheses). 
 
Supplementary Figure 4: Reference-based tumor deconvolution of the DNA methylome 
shows no major differences in cellular composition with regard to sample collection before 
or after onset of ICI treatment. 
DNA methylome-based tumor deconvolution was performed by the reference-based algorithms (A) 
LUMP and (B) MethylCIBERSORT. The LUMP estimate ratio and the proportions (in percent) of 
the respective cell type were compared in tissue prior (pre-ICI) and after (post-ICI) onset of ICI 
treatment using the non-parametric Wilcoxon’s test (significant p-values in bold italics, number of 
patients in parentheses).  
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